Iterum Therapeutics to Present at the 26th Annual H.C. Wainwright Global Investment Conference
2024年9月7日 - 5:30AM
Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a clinical-stage
pharmaceutical company focused on developing next-generation oral
antibiotics to treat infections caused by multi-drug resistant
pathogens in community settings, today announced that Corey
Fishman, Iterum's Chief Executive Officer, will present and host
investor meetings at the 26th Annual H.C. Wainwright Global
Investment Conference held September 9 to September 11, 2024, at
the Lotte New York Palace Hotel.
Admission to H.C. Wainwright's conference is for
qualified investors. Iterum will be giving a presentation at 8:30
am ET on September 10, 2024. Management will also be available for
one-on-one meetings onsite on September 10, 2024.
H.C. Wainwright 26th Annual Global Investment
Conference, New York, NY
Presentation Date: Tuesday, September 10,
2024
Presentation Time: 8:30 AM ET
1x1 Meetings: Please contact your HCW
representative
The webcast presentation replay will be
available for viewing on the Events & Presentations section of
Iterum’s website following the presentation.
About Iterum Therapeutics
plc
Iterum Therapeutics plc is a clinical-stage
pharmaceutical company dedicated to developing differentiated
anti-infectives aimed at combatting the global crisis of multi-drug
resistant pathogens to significantly improve the lives of people
affected by serious and life-threatening diseases around the world.
Iterum Therapeutics is advancing the development of its first
compound, sulopenem, a novel penem anti-infective compound, with an
oral formulation and IV formulation. Sulopenem has demonstrated
potent in vitro activity against a wide variety of gram-negative,
gram-positive and anaerobic bacteria resistant to other
antibiotics. Iterum Therapeutics has submitted an NDA for oral
sulopenem for the treatment of uncomplicated urinary tract
infections in adult women, which has been accepted for review by
the U.S. Food and Drug Administration and has received Qualified
Infectious Disease Product (QIDP) and Fast Track designations for
its oral and IV formulations of sulopenem in seven indications. For
more information, please visit http://www.iterumtx.com.
Investor Contact:Judy
Matthews Chief Financial Officer312-778-6073IR@iterumtx.com
Iterum Therapeutics (NASDAQ:ITRM)
過去 株価チャート
から 9 2024 まで 10 2024
Iterum Therapeutics (NASDAQ:ITRM)
過去 株価チャート
から 10 2023 まで 10 2024